Abstract：Objective: To explore the detection value of peripheral blood Th cells in hepatitis, cirrhosis and liver cancer. Methods: 91 patients with liver diseases admitted by our department from March 2017 to March 2018 were selected as subjects, among which 34 were patients with chronic hepatitis b, 31 were patients with liver cirrhosis and 26 were patients with liver cancer. Meanwhile, 30 healthy subjects with normal liver function were selected as the control group. Using enzyme-linked immunosorbent (ELISA) method above and the control group in the peripheral blood of patients with Th cytokines - Th1 class factor [interferon (IFN) - gamma, interleukin (IL) - 12, tumor necrosis factor (TNF) - alpha], Th2 factor [IL - 4), IL - 6, IL - 10], the cells and the determination of Th cells (CD3 +, CD4 +, CD8 +). Results: IL-2, IFN-gamma, TNF-a, IL-4 and IL-10 in hepatitis B group were higher than those in cirrhosis group, while IL-6 was lower than that in cirrhosis group (P<0.05). The levels of IL-12, IL-6 and IL-10 in the hepatitis b group were higher than those in the liver cancer group, while the levels of ifn-fractionation and TNF- were significantly lower than those in the liver cancer group (P<0.05). The levels of ifn-beta, TNF-, IL-4 and IL-10 in the liver cirrhosis group were lower than those in the liver cancer group and IL-6 was higher than those in the liver cancer group, with statistically significant differences (P<0.05). IL-12, ifn-beta, TNF-, IL-4, IL-6, and IL-10 in the hepatitis b group and the cirrhosis group were lower than those in the control group, with statistically significant differences (P<0.05). IL-12, ifn-fractionation, IL-4, IL-6, and IL-10 in the liver cancer group were all lower than those in the control group, with statistically significant differences (P<0.05). There were also statistically significant differences in CD3+, CD4+, CD8+ and CD4+/CD8+ between the hepatitis B group, the liver cirrhosis group and the liver cancer group (P<0.05). Conclusion: The expression of Th1 and Th2 cytokines is abnormal in patients with hepatitis, cirrhosis and hepatocellular carcinoma. The balance of Th1/Th2 is destroyed and the clearance of HBV virus is inhibited. The detection of Th1/Th2 cytokines in patients with hepatitis, cirrhosis and hepatocellular carcinoma should be emphasized
[1] 刘宁,徐杰,刘金花,等.慢性乙型肝炎、乙肝肝硬化、乙肝肝癌患者Thl／Th2型细胞因子水平变化研究[J].胃肠病学和肝病学杂志,2014,23(2):158~161. [2] 许秀华,向晓星,马莉,等.原发性肝癌患者外周血Th22细胞水平的变化及意义[J].中国免疫学杂志,2014,30(9):1245~1248,1250. [3] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941~1960. [4] Xia Y,Stadler D,Lucifora J,et al.Interferon-7 and tumor necrosis factor-a produced by T cells reduce the HBV persistence form cccDNA,without cytolysis[J].Gastroenterology,2016,150(1):194~205. [5] Lan T,Chang L,Wu L,et al.IL-6 Plays a crucial role in HBV infecfion[J].Clin Tmnsl Hepatol,2015,3(4):271~276. [6] 李铃敬,杨彬,刘娇,等.恩替卡韦对慢性乙型肝炎患者外周血Thl／Th2型细胞因子表达水平的影响[J].中华肝脏病杂志,2017,25(8):606~611. [7] Weiskirchen R ,Tacke F. Immune surveillance of liver cancer in non-alcoholic fatty liver disease : excess lipids cause CD4 T-cells loss and promote hepatocellular car-cinoma development [J].Hepatobiliary Surg Nutr,2016,5(5):433~437. [8] 程广霞,李建志,张俊,等.原发性肝癌血清细胞因子检测的临床意义[J].中国现代普通外科进展,2016,19(12):990~991,995. [9] 赵学涛,杨从容,任晓亮,等.红细胞输注对肝癌患者CD4+T辅助细胞免疫功能的影响[J].河北医科大学学报,2015,36(7):803~806. [10] 聂红明,汪蓉,朱梅萍,等.不同临床状态的HBV感染相关肝病患者T淋巴细胞水平和主要细胞因子表达的比较[J].中西医结合肝病杂志,2015,25(1):8~12. [11] 陈炜青,叶丽君,陈飞华,等.外周血HLA-G及血清Th1、Th2类细胞因子在肝癌患者中的检测价值研究[J].中国现代医生,2017,55(14):1~4. [12] 侯春阳,马玉梅,刘莉,等.慢性乙型肝炎及乙型肝炎后肝硬化、肝癌患者外周血辅助性T淋巴细胞表达水平分析[J].临床误诊误治,2017,30(5):98~101.
2019, Vol. 25 
冀公网安备13080202000677号